Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a lpv/r-containing haart: The atazip study

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 1, 2009, Pages 29-36

  Mallolas, Josep ^a   Podzamczer, Daniel ^b   Milinkovic, Ana ^a   Domingo, Pere ^c   Clotet, Bonaventura ^d   Ribera, Esteve ^e   Gutiérrez, Félix ^f   Knobel, Hernando ^g   Cosin, Jaime ^h   Ferrer, Elena ^b   Arranz, José Alberto ⁱ   Roca, Victor ^j   Vidal, Francesc ^k   Murillas, Javier ^l   Pich, Judit ^a   Pedrol, Enric ^m   Llibre, Josep M ⁿ   Dalmau, David ^o   García, Isabel ^p   Aranda, Miquel ^q   Cruceta, Ana ^m   Martínez, Esteban ^a   Blanco, José L ^a   Lazzari, Elisa De ^a   Gatell, José M ^a   more..

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d IrsiCaixa Foundation   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^j HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^k HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^l HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^m HOSPITAL GENERAL DE GRANOLLERS   (Spain)

ⁿ Hospital de Calella   (Spain)

^o HOSPITAL MÚTUA DE TERRASSA   (Spain)

^p Hospitalet de Llobregat   (Spain)

^q Terrasa Hospital Consorci Sanitari Terrassa   (Spain)

more..

Author keywords

Atazanavir; HAART; HIV; Lopinavir; Protease inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; LOPINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; JAUNDICE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT;

ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTATE AMINOTRANSFERASES; DRUG RESISTANCE, VIRAL; DRUG TOLERANCE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIPIDS; LIVER; MALE; MIDDLE AGED; MUTATION; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES; SAFETY;

EID: 67049130751     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31819a226f     Document Type: Article

References (19)

1. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. US Department of Health and Human Sevices; December 2007. Available at: http://aidsinfo.nih.gov. Accessed January 31, 2008.
2. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infec Dis. 2001;33:865-872.
3. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17:169-177.
4. Scott JD. Simplifying the treatment of HIV infection with ritonavirboosted protease inhibitors in antiretroviral-experienced patients. Am J Health Syst Pharm. 2005;62:809-815.
5. Moyle G. Metabolic issues associated with protease inhibitors. J Acquir Immune Defic Syndr. 2007;45 (Suppl 1):S19-S26.
6. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007;44:1484-1492.
7. Rubio R, Carmena J, Asensi V, et al. Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions: preliminary results of GESIDA 44/04 SIMPATAZ Study. Presented at the 11th European AIDS Conference; October 24-27, 2007; Madrid, Spain. Abstract 7.5/03.
8. Pineda JA, Palacios R, Rivero A, et al. Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. J Antimicrob Chemother. 2006;57:1016-1017.
9. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviralnaive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646-655.
10. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA. 1993;269:729-730.
11. Johnson VA, Brun-Vézinet F, Clotet B, et al. Drug resistance mutations in HIV-1 International AIDS Society-USA. Top HIV Med. 2004;12: 119-124. Available at: http://www.iasusa.org. Accessed March 31, 2008.
12. AIDS Clinical Trials Group. Table for grading severity of adult adverse experiences. August 1992. Available at: http://aactg.s-3.com/members/adulttox. htm. Accessed November 7, 2007.
13. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36:1011-1019.
14. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virological failures. AIDS. 2006;20:711-718.
15. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidaemia. J Acquir Immune Defic Syndr. 2005; 39:174-180.
16. Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr. 2004;36: 684-692.
17. Haas DW, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy:a randomized comparative pilot trial. AIDS. 2003;17:1339-1349.
18. Soriano V, García-Gasco P, Vispo E, et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viremia: final results of the SLOAT trial. J Antimicrob Chemother. 2008;61:200-205.
19. Molina JM. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs. 2008;68:567-578.